Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidence.

Item

http://www.wikidata.org/entity/Q37908174

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Histology as a treatment effec ...... ematic review of the evidence.

@en

Histology as a treatment effec ...... ematic review of the evidence.

@nl

type

Item

label

Histology as a treatment effec ...... ematic review of the evidence.

@en

Histology as a treatment effec ...... ematic review of the evidence.

@nl

prefLabel

Histology as a treatment effec ...... ematic review of the evidence.

@en

Histology as a treatment effec ...... ematic review of the evidence.

@nl

P1476

Histology as a treatment effec ...... ematic review of the evidence.

@en

P2093

Adèle R Weston

http://www.w3.org/2001/XMLSchema#string

Helen Barraclough

http://www.w3.org/2001/XMLSchema#string

Lachlan Standfield

http://www.w3.org/2001/XMLSchema#string

Maximiliano Van Kooten

http://www.w3.org/2001/XMLSchema#string

Nick Pavlakis

http://www.w3.org/2001/XMLSchema#string

P2860

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

Erlotinib in previously treated non-small-cell lung cancer

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients.

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.

Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial.

Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer.

Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group.

Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.

P304

1210-1220

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1440-1843.2011.02025.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21801275

http://www.w3.org/2001/XMLSchema#string